May 06, 2020
Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens
Jul 24, 2019
Cipla USA Furthers AMR Stewardship With Acquisition of Key Anti-infective ZEMDRI(TM) (IV Plazomicin)
Jun 13, 2019
Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting
Mar 18, 2019
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients
Nov 20, 2018
Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)
Jun 01, 2018
Successful USFDA inspection of Asymchem Fuxin 1 carbapenem manufacturing facility
Apr 05, 2018
New Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/Vaborbactam
Feb 01, 2018
FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Oct 04, 2017
Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017
Oct 02, 2017
FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)
Sep 28, 2017
Shionogi To Highlight Research On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188, A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At IDWeek 2017
Jun 01, 2017
Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe (ASM) Meeting